Legend Biotech is a global biotechnology company developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. The company has a global collaboration agreement with Janssen to jointly develop and commercialize ciltacabtagene autoleucel (cilta-cel) for multiple myeloma.
